KRYS (Krystal Biotech) FCF Margin % : 68.95% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Krystal Biotech's Free Cash Flow for the three months ended in Sep. 2024 was $57.8 Mil. Krystal Biotech's Revenue for the three months ended in Sep. 2024 was $83.8 Mil. Therefore, Krystal Biotech's FCF Margin % for the quarter that ended in Sep. 2024 was 68.95%.

As of today, Krystal Biotech's current FCF Yield % is 1.23%.

The historical rank and industry rank for Krystal Biotech's FCF Margin % or its related term are showing as below:

KRYS' s FCF Margin % Range Over the Past 10 Years
Min: -198.43 Med: -198.43 Max: 24.04
Current: 24.04

During the past 8 years, the highest FCF Margin % of Krystal Biotech was 24.04%. The lowest was -198.43%. And the median was -198.43%.

KRYS's FCF Margin % is ranked better than
93.01% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs KRYS: 24.04

Krystal Biotech FCF Margin % Historical Data

The historical data trend for Krystal Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech FCF Margin % Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-198.43

Krystal Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-268.90	-21.54	32.33	-7.54	68.95

Competitive Comparison of Krystal Biotech's FCF Margin %

For the Biotechnology subindustry, Krystal Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's FCF Margin % falls into.

Krystal Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Krystal Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-100.603	/	50.699
	=	-198.43 %

Krystal Biotech's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	57.811	/	83.841
	=	68.95 %

Krystal Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Executives

Krish S Krishnan	director, 10 percent owner, officer: President and CEO	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan	director, 10 percent owner, officer: Chief Operating Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Kathryn Romano	officer: Chief Accounting Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Andrew C. Orth	officer: Chief Commercial Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi	director	61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jennifer Chien	officer: Chief Commercial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby	director	C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v.	10 percent owner	POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000